



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)
A61P 35/02 (2006.01)

(21) International Application Number:

PCT/IB2020/000342

(22) International Filing Date:

11 March 2020 (11.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/816,464 11 March 2019 (11.03.2019) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: GANESAN, Rajkumar; Welsh and McKean Raods, Spring House, PA 19477 (US). GREWAL, Iqbal, S.; Welsh and McKean Raods, Spring House, PA 19477 (US). SEPULVEDA, Manuel, Alejandro; Welsh and McKean Raods, Spring House, PA 19477 (US).

(74) Agent: JONES DAY; Rechtsanwälte Attorneys-at-Law Patentanwälte, Prinzregentenstraße 11, 80538 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTI-V(BETA17)/ANTI-CD123 BISPECIFIC ANTIBODIES




FIG. 1

(57) Abstract: The present disclosure relates to Vβ17 /CD123 bispecific antibodies. The antibodies are characterized by their CDRs sequences. Toxicity experiments are performed on Kasumi-3 cells (used to perform acute myeloblastic leukaemia pathologies)



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

03 December 2020 (03.12.2020)

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2020/000342

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K39/395 A61P35/02 C07K16/28
 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 A61K A61P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2018/223002 A1 (XENCOR INC [US]) 6 December 2018 (2018-12-06) See claims	1-29
A	WO 2018/015340 A1 (SANOFI SA [FR]) 25 January 2018 (2018-01-25) See claims	1-29
A	US 6 084 087 A (FRIEDMAN STEVEN M [US] ET AL) 4 July 2000 (2000-07-04) See examples, claima	30-34

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 19 October 2020	Date of mailing of the international search report 28/10/2020
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Nauche, Stéphane
--	---

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2020/000342

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-29

VBeta17/CD123 bispecific antibodies, method of production and uses in cancer therapy

2. claims: 30-34

Vbeta17 antibodies, method of production and uses in cancer therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/IB2020/000342

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2018223002	A1	06-12-2018	
		AU 2018275109 A1	02-01-2020
		CA 3065929 A1	06-12-2018
		CN 111344303 A	26-06-2020
		EP 3630839 A1	08-04-2020
		JP 2020522498 A	30-07-2020
		KR 20200041834 A	22-04-2020
		US 2020181274 A1	11-06-2020
		WO 2018223002 A1	06-12-2018

WO 2018015340	A1	25-01-2018	
		AR 109264 A1	14-11-2018
		AU 2017299125 A1	07-03-2019
		BR 112019000770 A2	02-07-2019
		CA 3030943 A1	25-01-2018
		CL 2019000119 A1	14-06-2019
		CN 109715665 A	03-05-2019
		CO 2019001367 A2	19-02-2019
		CR 20190072 A	25-06-2019
		DO P2019000011 A	15-05-2019
		EA 201990321 A1	28-06-2019
		EC SP19011185 A	28-02-2019
		EP 3484924 A1	22-05-2019
		JP 2019531701 A	07-11-2019
		KR 20190028771 A	19-03-2019
		PE 20190514 A1	10-04-2019
		PH 12019500122 A1	15-04-2019
		SG 11201900400Q A	27-02-2019
		TN 2019000015 A1	15-07-2020
		TW 201811830 A	01-04-2018
		US 2019241657 A1	08-08-2019
		WO 2018015340 A1	25-01-2018

US 6084087	A	04-07-2000	
		US 6084087 A	04-07-2000
		US 6303750 B1	16-10-2001
